galantamin orion 24 mg depotkapseli, kova
orion corporation - galantamine hydrobromide - depotkapseli, kova - 24 mg - galantamiini
galantamin stada 8 mg depotkapseli, kova
stada arzneimittel ag - galantamine hydrobromide - depotkapseli, kova - 8 mg - galantamiini
galantamin stada 16 mg depotkapseli, kova
stada arzneimittel ag - galantamine hydrobromide - depotkapseli, kova - 16 mg - galantamiini
galantamin stada 24 mg depotkapseli, kova
stada arzneimittel ag - galantamine hydrobromide - depotkapseli, kova - 24 mg - galantamiini
queloran 50 mg depottabletti
pharmathen s.a. pharmathen s.a. - quetiapini fumaras - depottabletti - 50 mg - ketiapiini
queloran 150 mg depottabletti
pharmathen s.a. pharmathen s.a. - quetiapini fumaras - depottabletti - 150 mg - ketiapiini
queloran 200 mg depottabletti
pharmathen s.a. pharmathen s.a. - quetiapini fumaras - depottabletti - 200 mg - ketiapiini
queloran 300 mg depottabletti
pharmathen s.a. pharmathen s.a. - quetiapini fumaras - depottabletti - 300 mg - ketiapiini
queloran 400 mg depottabletti
pharmathen s.a. pharmathen s.a. - quetiapini fumaras - depottabletti - 400 mg - ketiapiini
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.